Publication | Forbes

The Cynicism of Biden’s High-Risk, Low-Reward Vaccine Patent Waiver

Harry Broadman

May 31, 2021

Harry Broadman writes about the Biden administration’s announcement about the willingness of Washington to temporarily waive patent protection of vaccines for COVID-19 developed and produced by pharmaceutical companies in the name of accelerating the inoculation of mass population segments of poor countries ravaged by the disease. He also discusses the authority for the federal government to procure vaccines from US pharmaceutical companies and others to deploy them in such countries.

Read the article.


Related Professionals

Harry G. Broadman

Managing Director

Washington, DC